CClinicalTrials.gg
CompletedNCT02224885Updated Apr 27, 2016

Needle-based Confocal Laser Endomicroscopy in Fluoroscopy-guided Procedures

An interventional study of CT-guided percutaneous biopsy or ablation in Lung Percutaneous Biopsy and Liver Percutaneous Biopsy, sponsored by Mauna Kea Technologies. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Mauna Kea Technologies · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a prospective study in order to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure in two main indications: lung and liver.

This innovative study will involve the use of probe-based confocal laser endomicroscopy. The proposed study is a feasibility study.

Read the detailed description

Interventional radiology is a medical sub-specialty of radiology which utilizes minimally-invasive image-guided procedures to diagnose and treat diseases in nearly every organ. The concept behind interventional radiology is to diagnose and treat patients using less invasive techniques currently available in order to minimize risk to the patient and improve health outcomes.

For many years, surgery was the only treatment available for many conditions. Today, interventional radiology treatments are frst-line care for a wide variety of conditions. Patients should be offered the least invasive option frst. It is important to get a second opinion and know all of your treatment options before consenting to any procedure or surgery. Interventional radiologists are specialists in minimally invasive treatments, have a unique breadth of training and provide consults to every type of specialist.

Surgical removal of liver tumors offers the best chance for a cure. Unfortunately, liver tumors are often inoperable because the tumor may be too large, or has grown into major blood vessels or other vital structures. Sometimes, many small tumors are spread throughout the liver, making surgery too risky or impractical. Surgical removal is not possible for more than two-thirds of primary liver cancer patients and 90 percent of patients with secondary liver cancer.

The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure in two main indications: lung and liver.

The goal is to determine whether:

  • Cellvizio insertion during the interventional procedure leads to change in known adverse events / serious adverse events rate during and one month after the procedure
  • It is technically feasible to obtain images from Cellvizio during an interventional radiology procedure
  • Cellvizio is a helpful assistance to increase the efficacy of biopsy which require to evaluate its accuracy eg. the predictive value of Cellvizio compared to pathology results.

Secondary goals are to assess:

  • Benefit of spatial accuracy for the yield of the biopsy procedure and potential subsequent intervention, e.g. radiofrequency ablation.
  • Regarding lung biopsies and lung ablation, potential increase of a database to refine image interpretation criteria with pathologists.
  • In liver application, the goal is to build a database of images and define image interpretation criteria with pathologists to start image interpretation work.
  • The predictive value of biopsies with Cellvizio assistance for lung or liver tumor biopsies.

For both applications, technical feedback from the physicians is expected on how they think the combined use of the devices could change the care path. E.g. a certain step in the workflow might become obsolete or the workflow could lead to fewer patient visits.

For the safety of this protocol, the use of endomicroscopy will not change in any way the patient management and standard procedure, including the diagnosis nor treatment decisions. All the adverse events / serious adverse events will be noted during the procedure and one week after the procedure.

02

Conditions studied

  • Lung Percutaneous Biopsy
  • Liver Percutaneous Biopsy

Keywords

  • Interventional radiology
  • Lung
  • Liver
  • Confocal endomicroscopy
  • Optical biopsy
  • Scanner
  • Fluoroscopy
  • CT
  • Computed Tomography
  • Radiofrequency Ablation
  • Fluorescein
03

In context

Lead sponsor

Mauna Kea Technologies is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients scheduled to have an interventional radiology procedure for needle-biopsy or radiofrequency ablation purposes in lung or in liver, 18 years or older.
  • Only subjects who have provided written informed consent for the study can be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to fluorescein
  • Previous life-threatening allergic reactions and known hypersensitivity to contrast media
  • Pregnancy or breast-feeding
  • History of cardio-pulmonary disease (including bronchial asthma)
  • Restricted renal function
  • Elderly with diabetes mellitus
  • Patients under a beta-blockers treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    addition of nCLE to help target biopsy

    The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.

    Device: CT-guided percutaneous biopsy or ablation

Interventions

  • DeviceCT-guided percutaneous biopsy or ablation

    Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung

06

What researchers measure

Primary outcomes

  1. Measure adverse events frequency in the use of mini probes on the tumor

    Assessment of the safety of inserting Cellvizio confocal miniprobe in the tumor (nor increase in bleeding or tumor cell dissemination) through the frequency, type and severity of adverse events

    Time frame: Up to 1 week

Secondary outcomes

  1. Creation of image bank

    A frst creation of an atlas of endomicroscopic images obtained in interventional radiology in the liver - for the lung, the atlas established for peripheral lung nodules in bronchoscopy applications will serve as a reference and will be tested prospectively.

    Time frame: Up to 6 months

  2. Yield of nCLE (needle-based confocal laser endomicroscopy)-targeted Fluoroscopy-guided biopsies

    Yield of nCLE (needle-based confocal laser endomicroscopy)-targeted Fluoroscopy-guided biopsies to assess improvements compared to standard of care from guidance function of the device combination.

    Time frame: Up to 5 months

  3. Evaluation of potential benefits of the device combination

    Potential clinical, operational and financial benefits of the combination of Mauna Kea Technologies' endomicroscopic solution and Siemens' C-arm solution derived from the improved decision making for treatment of lung and liver lesions during the procedure (a clinical benefit could be fewer negative biopsies; an operational benefit could be one step fewer in the care path and a financial benefit could be a quicker diagnosis/treatment time, thus being able to release the patient earlier).

    Time frame: Up to 5 months

  4. Assessment of accuracy and predictive value of interpretation criteria

    Evaluation of the predictive value of Cellvizio as an increasing tool of biopsy performance.

    Time frame: Up to 5 months

07

Study locations

1 site
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02224885
Lead sponsor
Mauna Kea Technologies
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Jan 2015
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Apr 27, 2016

Study contacts

Olivier PELLERIN
principal investigator · HEGP, Paris, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion